-
EMERcell
- Project Leader
2016 - maintenant
Emercell is an emerging independently funded biotech company, developing projects in the fields of immunotherapy and cell therapy.
NK 001. Aimed at producing a new advanced therapy medicinal product directed towards the treatment of AML, (Acute Myeloid Leukemia), this project uses a patented process to pre-activate and amplify the effects of the allogeneic NK (Natural Killer) cells.
The impact of the association between Emercell NK and monoclonal antibodies directed against tumor antigens is also currently being evaluated.
A collaborative program has been created around the NK-001 project. This program has been chosen by the FUI to perform the preclinical studies and the first clinical trial if such should prove possible.
Emercell has developed a number of collaborative projects with industrial partners, focusing on the study of the activity of NK Cells in association with MAbs.
-
INM montpellier
- Principal scientist (Post doc)
2013 - 2016
Drug development and drug delivery. Preclinical study. Pharmacology. Innovation: Formulation, design, chemical modification (vectorization, alkylation), in vitro (ARPE19 cell line & primary culture of photoreceptor) and in vivo (ABCA4KO mouse model) efficiency & toxicity. Challenging retinal degeneration (AMD, Stargardt disease). Focus on photoreceptor degeneration induced by all trans retinaldehyde toxicity. Study of oxidative and carbonyl stresses.
Lipid metabolism: In vivo study (FATP mouse model), lipid dosage, IF & IHC, lipid quantification, mitochondrial function, enzymology, autophagy. Focus on Retinal Pigmented Epithelium physiopathology and photoreceptor development.
Project management. Quality Data Management and corrective actions. Supervisory staff (5) Editorial and analytic mind Communication. Funding research and Business Development. Clinical. Planning. Alliance partnerships. Leadership.
Caudalie & Pr C. Hamel INM/CHU Gui de Chauliac Montpellier
-
CNRS-IGMM
- Principal scientist (PhD and post doc)
Paris
2009 - 2013
Gene therapy. Vectorology. Neuroscience: Gene transfer to the CNS and cornea (human explant and mouse, dog and monkey models). Stereotactic injections, lysosomal study, enzymology, Immune response (blood & serum, NAB, PBMC). Inflammation (Cytokine, Macrophages,CD4, CD8). HD vector production, purification and quality control. Cloning, vector design and construction. Respect of GMP for clinical trial.
Project management. Quality Data Management and corrective actions Supervisory staff (3). Communication. Planning. Partnership and work in international and multidisciplinary teams (EU). Training. Dr E. Kremer. IGMM Montpellier
-
IRD-LIN
- Technician
2009 - 2009
Control and Strategies to fight pests. Entomology. Chikungunya. In charge of pests facility. In vivo shRNA injection. Test and selection of new insecticides.
-
IRB montpellier
- Intern
2007 - 2008
Bio-informatics & algorithm
Transcriptome of hematopoietic stem cells, microarray, exome. Splicing. Clinical activity. Leukemia. Reporting. Analytic mind. Statistic.
Pr J. De Vos, A. de Villeneuve IRMB- Montpellier
-
IGMM montpellier
- Intern
2007 - 2007
Oncology. Tumoral angiogenesis. In vivo delivery of tumoral cells. Cloning. Reporting.
-
Ontex
- Manager
2006 - 2006
Quality control. Industrial chain. Biophysics. Chemistry. Quality report. Production line manager.
-
Bouisson Bertrand Montpellier
- Technician
2005 - 2005
Microbiology. Chemistry. Food and water analyses. Quality report. Scientific monitoring.